Stemline Therapeutics' (STML) SL-401 Receives FDA Breakthrough Therapy Designation as BPDCN Treatment
Tweet Send to a Friend
Stemline Therapeutics, Inc. (Nasdaq: STML) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE